The company reported no revenues in Q3 but said it has completed the transition to a new diagnostic platform for its DetermaVu liquid biopsy lung cancer test.
The company reported total revenues of $761,591 from the accession of 878 billable samples, 27 percent fewer than the same quarter last year.
The firm's technology uses DNA sequencing, artificial intelligence, and a microbial database to interpret soil health and identify potential disease risk.
The contract covers Bio-Rad's iQ-Check RT-PCR pathogen detection test kits, which cover pathogens including Salmonella spp. and Listeria monocytogenes.
The tests from Asuragen and MolecularMD are designed for use in chronic myeloid leukemia patients, including those receiving tyrosine kinase inhibitor therapy.
This test is the firm's second assay on the point-of-care Accula molecular diagnostics system.
The BioFire FilmArray Pneumonia Panel was cleared by the FDA while the BioFire FilmArray Pneumonia Panel Plus was CE marked.
OMI researchers will apply and validate 1CellBio's inDrop system to generate predictive data for patients with undiagnosed immune dysfunction conditions.
Guardant's lab will make Guardant360 available to doctors and their patients in the region to help identify patients eligible for molecularly targeted drugs.
Researchers found that methylation alterations affected immune response and lipid metabolism pathways in children whose growth had been stunted.
Researchers used an integrated analysis to find regulatory and transcriptional networks coinciding with specific DNA mutation subtypes in AML.
Last week, GenomeWeb's readers were most interested in two recent actions from the FDA on PGx testing that have manufacturers, labs, and doctors confused.
Oxford BioDynamics will work with Italian research institute Casa Sollievo della Sofferenza to identify blood-based biomarkers of autism spectrum disorder.
GWAS summary statistics data led to three main loci with ties to both Alzheimer's and cardiovascular disease, with additional enrichment at lipid-related sites.
At least some variants associated with benign prostatic hyperplasia appeared to contribute to PSA levels in the blood, independent of prostate cancer.
The projects are organized by the Eliminate Cancer Initiative, the National Brain Tumor Society, and the Pediatric Brain Tumor Foundation.
HTG missed the analysts' average estimate on the top line but beat expectations on the bottom line. It guided to full-year 2018 revenues of $21 million to $25 million.
The molecular diagnostics firm grew year-over-year testing volumes by 28 percent to 167,172.
The company beat Wall Street estimates, and officials said momentum is building as the firm readies its GeoMx digital spatial profiling technology for launch.
The company said testing services revenues more than doubled during the quarter as its AlloSure kidney transplant diagnostic continued to penetrate the market.
The firm will use the funding to advance commercialization of its RNA disruption assay and continue its breast cancer response therapy trial.
The firm signed four new distribution deals to spread its products into more than a dozen new markets.
The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.
In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.
The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.
In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.